L'intérêt à découvert pour HUTCHMED (China) donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de HUTCHMED (China). Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

HUTCHMED (China) (NASDAQ:HCM) Stock, Rapport sur les intérêts à découvert

HUTCHMED (China)

HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China) Ltd

HCM ACQUISITION CORP USD CL A ORD SHS

HCM ACQUISITION CORP USD UNITS CONSISTING ONE CL A ORD SH OF $0.0001 PAR VALUE &

HCM ACQUISITION CORP USD RED WTS

HEALTHIER CHOICES MGMT by Healthier Choices Management Corp.

Healthier Choices Management Corp

Holcim Ltd

Direxion Shares ETF Trust Direxion HCM Tactical Enhanced US ETF

Sapiens International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPNS#NASDAQ">SPNS</a>) raises FY2025 sales outlook from $553.00 million-$558.00 million to $574.00 million-$578.00 million.

News

Guidance

SPNS

Sapiens International Raises FY2025 Sales Guidance from $553.00M-$558.00M to $574.00M-$578.00M

Wolverine World Wide (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WWW#NYSE">WWW</a>) is looking for Q2 GAAP EPS of $0.17-$0.22 vs $0.26 analyst estimate..

Wolverine World Wide Sees Q2 GAAP EPS $0.17-$0.22 vs $0.26 Est

Wolverine World Wide (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WWW#NYSE">WWW</a>) is looking for Q2 Adj EPS of $0.19-$0.24 vs $0.24 analyst estimate. sees sales of $440.000 million-$450.000 million vs $440.37 million analyst estimate.

Wolverine World Wide Sees Q2 Adj EPS $0.19-$0.24 vs $0.24 Est; Sees Sales $440.000M-$450.000M vs $440.37M Est

First Advantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FA#NASDAQ">FA</a>) affirms FY2025 Adj EPS guidance from $0.86-$1.03 to $0.86-$1.03 vs $0.90 analyst estimate. Affirms FY2025 sales outlook from $1.50 billion-$1.60 billion to $1.50 billion-$1.60 billion vs $1.51 billion estimate.

First Advantage Affirms FY2025 Adj EPS Guidance of $0.86-$1.03 vs $0.90 Est; Affirms FY2025 Sales Guidance of $1.50B-$1.60B vs $1.51B Est

Needham analyst Scott Berg reiterates Dayforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAY#NYSE">DAY</a>) with a Buy and maintains $95 price target.

Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on Dayforce, Maintains $95 Price Target

First Advantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FA#NASDAQ">FA</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.13 by 30.77 percent. This is unchanged from the same period last year. The company reported quarterly sales of $354.59 million which beat the analyst consensus estimate of $344.34 million by 2.98 percent. This is a 109.30 percent increase over sales of $169.42 million the same period last year.

Earnings

Earnings Beats

First Advantage Q1 Adj. EPS $0.17 Beats $0.13 Estimate, Sales $354.59M Beat $344.34M Estimate

Wolverine World Wide (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WWW#NYSE">WWW</a>) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.11 by 63.64 percent. This is a 260 percent increase over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $412.30 million which beat the analyst consensus estimate of $395.69 million by 4.20 percent. This is a 4.41 percent increase over sales of $394.90 million the same period last year.

Wolverine World Wide Q1 Adj. EPS $0.18 Beats $0.11 Estimate, Sales $412.30M Beat $395.69M Estimate

CORRECTION: Genesis Energy Q1 EPS $(0.60) Down From $(0.15) YoY, Sales $398.31M Down From $434.45M YoY

WestPark Capital analyst Curtis Shauger reiterates Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) with a Buy and maintains $210 price target.

GOOGL

WestPark Capital Reiterates Buy on Alphabet, Maintains $210 Price Target

Sapiens Intl Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPNS#NASDAQ">SPNS</a>) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.35 by 5.71 percent. This is a 2.78 percent increase over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $136.10 million which missed the analyst consensus estimate of $136.25 million by 0.11 percent. This is a 1.38 percent increase over sales of $134.25 million the same period last year.

Earnings Misses

Sapiens Intl Corp Q1 Adj. EPS $0.37 Beats $0.35 Estimate, Sales $136.10M Miss $136.25M Estimate

U.S. stock futures rose on Thursday after two days of advance on Wednesday. Futures of major benchmark indices were higher in premarket.
This followed the Federal Reserve&#8217;s <a href="https://www.benzinga.com/government/regulations/25/05/45266366/powell-flags-sharp-tariff-shock-elevated-uncertainty-fed-sticks-to-wait-and-see-mode">decision to hold the interest rate</a> steady at 4.25% to 4.5% on Wednesday. 
"The tariff increases announced so far have been significantly larger than anticipated," Fed Chair Jerome Powell said.
He noted that if the tariffs are sustained, they could lead to higher inflation, weaker growth, and a rise in unemployment, directly undermining the Fed&#8217;s dual mandate.
"We don&#8217;t think we need to be in a hurry. We are going to be watching the data. It may move quickly or slowly. But we&#8217;re well-positioned to wait," he said.
Meanwhile, the 10-year Treasury bond yielded 4.31% and the two-year bond was at 3.82%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing a 79.8% likelihood of the Federal Reserve keeping the current interest rates unchanged in its June meeting.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.72%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.94%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>1.38%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.31%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Thursday. The SPY was up 1.14% to $567.54, while the QQQ advanced 1.51% to $490.61, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Leading the gains among sectors in the S&amp;P 500 on Wednesday were health care, consumer discretionary, and information technology stocks, as most sectors closed positively.
Bucking this trend were communication services and materials stocks, which finished the session lower.
In company news, Uber Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) reported first-quarter revenue that fell short of expectations, while Walt Disney Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) announced positive fiscal second-quarter 2025 results on Wednesday.
On the economic front, U.S. mortgage application volumes saw an 11% increase from the prior week for the week ending May 2nd.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.27%</td>
<td>17,738.16</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.43%</td>
<td>5,631.28</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.70%</td>
<td>41,113.97</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.33%</td>
<td>1,989.66</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Sharing a<a href="https://www.benzinga.com/general/market-summary/25/05/45278334/sp-500-chart-indicates-adding-long-positions-as-expert-says-market-has-found-its-balance?utm_campaign=Watchlist&amp;utm_source=Benzinga&amp;utm_medium=Email"> 10-year S&amp;P 500 chart</a> on X, Jurrien Timmer, Director of Global Macro at Fidelity Investments, offered a simple yet thought-provoking approach to navigating uncertainty.
He suggested considering whether to take a long or short position based on the index&#8217;s historical performance. Analyzing the technical patterns, Timmer concluded that establishing or increasing &#8220;long&#8221; positions appeared to be the more favorable strategy.
Timmer stated that the S&amp;P 500 appears to have gravitated back to this long-term uptrend line. This convergence, according to Timmer, suggests that the &#8220;market has found its balance.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">At times of uncertainty, I find it useful to pull up a simple chart of the S&amp;P 500 and ask myself: do I want to be long or short this chart? Different people will come up with different answers, but for me the chart below suggests "long." We have a rising uptrend line and a… <a href="https://t.co/DsLOxYz6sn">pic.twitter.com/DsLOxYz6sn</a>
&mdash; Jurrien Timmer (@TimmerFidelity) <a href="https://twitter.com/TimmerFidelity/status/1920148872690532867?ref_src=twsrc%5Etfw">May 7, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Scott Wren, the senior global market strategist at Wells Fargo, stated in his weekly note that &#8220;Further near-term upside in the S&amp;P 500 Index is likely limited, and we expect to see more downside volatility before the tariff uncertainties are resolved.&#8221;
According to Wren, central bankers keep telling us they are "data dependent." That means Chair Powell and the other voting Federal Open Market Committee members need to see the data that tells the Federal Reserve the labor environment is weak and/or inflation readings are coming down consistently.
&#8220;In the meantime, we are looking into 2026 and seeing an economic and earnings recovery. For now, while volatility remains the likely headline, we prefer to focus on quality, like large- and mid-cap U.S. equities, and favor the Energy, Communication Services, Information Technology, and Financials sectors,&#8221; he added.
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Thursday:
<ul>
<li>Initial jobless claims for the week ended May 3 and U.S. productivity data for the first quarter will be released by 8:30 a.m. ET.</li>
</ul>
<ul>
<li>March&#8217;s wholesale inventories data will be out by 10:00 a.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>US Foods Holding Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>) fell 0.17% in premarket on Thursday as it is expected to report earnings before the opening bell. Analysts expect a quarterly earnings of 69 cents per share on revenue of $9.38 billion.</li>
<li>ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) was up 1.35% as Wall Street expects it to report earnings of 50 cents per share on revenue of $11.62 billion before the opening bell.</li>
<li>Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) jumped 4.53% as it is expected to report earnings before the opening bell. Analysts expect a quarterly earnings of 69 cents per share on revenue of $9.38 billion.</li>
<li>Anheuser-Busch Inbev SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUD#NYSE">BUD</a>) rose 2.55% after reporting a 7.9% increase in operating profit for the first quarter, also topping market estimates.</li>
<li>Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) dropped 9.31% after posting a wider-than-expected loss for the first quarter after the closing bell on Wednesday. The company also said it expects full-year 2025 steel unit cost reductions of approximately $50 per net ton compared to the prior year.</li>
<li>Digital Ally Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) jumped 64.49% after it received a positive determination from the Nasdaq Hearings Panel regarding its continued listing on the Nasdaq Stock Market.</li>
<li>Costamare Bulkers Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMDB#NYSE">CMDB</a>) zoomed 40.27%, announced today that it has completed the spin-off of its dry bulk business into a standalone public company, Costamare Bulkers Holdings Ltd.</li>
<li>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) was 0.82% higher after China Airlines announced an order including Boeing 777X passenger and freighter models.</li>
<li>Asset Entities Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>) skyrocketed 54.57% after it entered into a definitive merger agreement with Strive Asset Management, a subsidiary of Strive Enterprises, Inc.</li>
<li>Beyond Meat Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYND#NASDAQ">BYND</a>) declined 2.36% after missing analysts&#8217; expectations during the first quarter.</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) jumped 4.21% after the company reported better-than-expected results during the first quarter.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 1.10% to hover around $58.71 per barrel.
Gold Spot US Dollar fell 0.77% to hover around $3,338.64 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was higher by 0.45% at the 100.0640 level.
Asian markets ended higher on Wednesday except India's S&amp;P BSE Sensex. On the other hand, Japan's Nikkei 225, Australia's ASX 200, China&#8217;s CSI 300, Hong Kong's Hang Seng, and South Korea's Kospi index rose. European markets were mixed in early trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/05/45251508/warren-buffett-falls-behind-nancy-pelosi-in-stock-market-returns-over-the-last-11-years-heres-what-data-shows">Warren Buffett Falls Behind Nancy Pelosi In Stock Market Returns Over The Last 11 Years: Here&#8217;s What Data Shows</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Market Summary

Futures

Technicals

Treasuries

Economics

Federal Reserve

Pre-Market Outlook

Markets

Trading Ideas

ASST

BYND

CMDB

COIN

CVNA

DGLY

UBER

USFD

US Stocks Likely To Open Higher After Two Days Of Advance: 'Market Has Found Its Balance,' Says Expert Citing S&P 500's Technical Analysis

Solidion's patented platform technology is capable of converting current lithium-ion facilities into producers of solid-state batteries

Solidion Unveils Patented Technology To Transform Lithium-Ion Facilities Into Solid-State Battery Producers

SGMT

Sagimet Biosciences Q1 2025 EPS $(0.56) Beats $(0.65) Estimate, Cash, Cash Equivalents And Marketable Securities As Of March 31, 2025, Were $144.6M

Enerflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFXT#NYSE">EFXT</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.12 by 58.33 percent. This is a 272.73 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $552.00 million which missed the analyst consensus estimate of $576.33 million by 4.22 percent. This is a 13.48 percent decrease over sales of $638.00 million the same period last year.

EFXT

Enerflex Q1 EPS $0.19 Beats $0.12 Estimate, Sales $552.00M Miss $576.33M Estimate

Ambev (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABEV#NYSE">ABEV</a>) reported quarterly earnings of $0.04 per share which met the analyst consensus estimate. This is a 20 percent decrease over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $3.84 billion which missed the analyst consensus estimate of $4.03 billion by 4.67 percent. This is a 6.20 percent decrease over sales of $4.10 billion the same period last year.

ABEV

Ambev Q1 Adj. EPS $0.04, Inline, Sales $3.84B Miss $4.03B Estimate

TD Securities analyst Andrew Charles reiterates Dutch Bros (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) with a Buy and maintains $78 price target.

BROS

TD Securities Reiterates Buy on Dutch Bros, Maintains $78 Price Target

EPAM Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>) is looking for Q2 Adj EPS of $2.56-$2.64 vs $2.47 analyst estimate. sees sales of $1.330 billion vs $1.30 billion analyst estimate.

EPAM

EPAM Systems Sees Q2 Adj EPS $2.56-$2.64 vs $2.47 Est; Sees Sales $1.330B vs $1.30B Est

Jinko ESS Partners With SolarToday To Deliver SunGiga All-In-One Products Across Benelux, Romania, Greece, Germany, And Turkey

EPAM Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>) raises FY2025 Adj EPS guidance from $10.45-$10.75 to $10.70-$10.95 vs $10.50 analyst estimate. Raises FY2025 sales outlook from $5.20 billion-$5.39 billion to $5.27 billion-$5.41 billion vs $5.27 billion estimate.

EPAM Systems Raises FY2025 Adj EPS Guidance from $10.45-$10.75 to $10.70-$10.95 vs $10.50 Est; Raises FY2025 Sales Guidance from $5.20B-$5.39B to $5.27B-$5.41B vs $5.27B Est

Maple Leaf Foods expects FY 2025 Revenue growth in the mid-single-digit range

Press Releases

HUTCHMED to Announce 2024 Final Results

Management

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

Health Care

HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

HUTCHMED Reports 2024 Full Year Results and Provides Business Updates

General

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

HUTCHMED (China)

Intérêt court

HUTCHMED (China) (NASDAQ:HCM) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL